Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR

Clinica Chimica Acta

Volumn 412, Issue 21-22, 2011, Pages 1905-1911

  Zhong, Yanwei ^a   Han, Jiaqi ^a   Zou, Zhengsheng ^a   Liu, Shuhong ^a   Tang, Bo ^a   Ren, Xiaoqiang ^a   Li, Xiaodong ^a   Zhao, Yulai ^a   Liu, Yan ^a   Zhou, Dongqing ^a   Li, Weijie ^a   Zhao, Jingmin ^a   Xu, Dongping ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

CccDNA; Hepatitis B virus; Quantitation; Rolling circle amplification

Indexed keywords

ALANINE AMINOTRANSFERASE; CIRCULAR DNA; DEOXYRIBONUCLEASE; HEPATITIS B(E) ANTIGEN; PLASMID SAFE ADENOSINE TRIPHOSPHATE DEPENDENT DEOXYRIBONUCLEASE; PRIMER DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BETA ACTIN GENE; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; ROLLING CIRCLE AMPLIFICATION; SENSITIVITY AND SPECIFICITY;

DNA, CIRCULAR; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HUMANS; LIVER; MALE; PARAFFIN EMBEDDING; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 80051679793     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.031     Document Type: Article

References (43)

1. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European association for the study of the liver.
2. Chinese Medical Association, The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol) 2011, 19:19-24. Chinese Society of Hepatology and Chinese Society of Infectious Diseases.
3. Papatheodoridis G.V., Manolakopoulos S., Dusheiko G., Archimandritis A.J. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008, 8:167-178.
4. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005, 42:302-308.
5. Laras A., Koskinas J., Dimou E., Kostamena A., Hadziyannis S.J. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006, 44:694-702.
6. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009, 51:581-592.
7. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
8. Sung J.J., Wong M.L., Bowden S., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
9. Bourne E.J., Dienstag J.L., Lopez V.A., Kostamena A., Hadziyannis S.J. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat 2007, 14:55-63.
10. Pawlotsky J.M., Dusheiko G., Hatzakis A., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized. Gastroenterology 2008, 134:405-415.
11. Takkenberg R.B., Zaaijer H.L., Niet A.D., et al. End of treatment intrahepetic hepatitis B (HBV) covalently closed circular DNA (cccDNA) predicts sustained virological response in chronic hepatitis B (CHB) patients treated with peginterferon alfa-2a and adefovir. Hepatology 2009, 50:535A-536A.
12. Lenci I., Marcuccilli F., Tisone G., et al. Total and covalently closed circular DNA detectioon in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. Dig Liver Dis 2010, 42:578-584.
13. Lu L., Zhang H.Y., Yueng Y.H., et al. Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients. J Viral Hepat 2009, 16:104-112.
14. Mazet-Wagner A.A., Baclet M.C., Loustaud-Ratti V., Denis F., Alain S. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods 2006, 138:70-79.
15. Kock J., Theilmann L., Galle P., Schlicht H. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 1996, 23:405-413.
16. Addison W.R., Wong W.W., Fischer K.P., Tyrrell D.L. A quantitative competitive PCR assay for the covalently closed circular form of the duck hepatitis B virus. Antiviral Res 2000, 48:27-37.
17. He M.L., Wu J., Chen Y., Lin M.C., Lau G.K., Kung H.F. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun 2002, 295:1102-1107.
18. Jun-Bin S., Zhi C., Wei-Qin N., Jun F. A quantitative method to detect HBV cccDNA by chimeric primer and real-time polymerase chain reaction. J Virol Methods 2003, 112:45-52.
19. Wong D.K., Yuen M.F., Yuan H., et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004, 40:727-737.
20. Bowden S., Jackson K., Littlejohn M., Locarnini S. Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol Med 2004, 95:41-50.
21. Singh M., Dicaire A., Wakil A.E., Luscombe C., Sacks S.L. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightcyclerTM real-time PCR. J Virol Methods 2004, 118:159-167.
22. Takkenberg R.B., Zaaijer H.L., Molenkamp R., et al. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. J Med Virol 2009, 81:988-995.
23. Takkenberg R.B., Zaaijer H.L., Menting S., et al. Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2010, 22:952-960.
24. Gao Y.T., Han T., Li Y., et al. Enhanced specificity of real-time PCR for measurement of hepatitis B virus cccDNA using restriction endonuclease and plasmid-safe ATP-dependent DNase and selective primers. J Virol Methods 2010, 169:181-187.
25. Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology Management scheme of diagnostic and therapy criteria of viral hepatitis. Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol) 2000, 6:324-329.
26. Xu D., Fu J., Jin L., et al. Circulating and liver resident CD4±CD25±regulatory T cells in circulation and liver actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-747.
27. Liu Y., Zhong Y., Zou Z., et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol 2010, 47:243-247.
28. Li X., Wang L., Zhong Y., et al. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol 2010, 48:4363-4369.
29. Liu Y., Wang C., Zhong Y., et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analog(s)-experienced Chinese patients with chronic HBV infection. J Viral Hepat 2011, 18:e29-e39.
30. Ji D., Liu Y., Si L.L., et al. Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients. Clin Chim Acta 2011, 412:305-313.
31. Weinberger K.M., Wiedenmann E., Böhm S., Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 2000, 85:75-82.
32. Wong D.K., Yuen M.F., Poon R.T., Yuen J.C., Fung J., Lai C.L. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 2006, 45:553-559.
33. Koch S., Freytag von Loringhoven A., Kahmann R., Hofschneider P.H., Koshy R. The genetic organization of integrated hepatitis B virus DNA in the human hepatoma cell line PLC/PRF/5. Nucleic Acids Res 1984, 12:6871-6886.
34. Chen Y., Sze J., He M.L. HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J Gastroenterol 2004, 10:82-85.
35. Yuen M.F., Wong D.K., Sum S.S., et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol 2005, 100:1099-1103.
36. Zhong Y.W., Liang Z.L., Ren X.Q., et al. Quantitative detection of hepatitis B virus covalently closed circular DNA in sera of chronic hepatitis B patients with a newly established assay. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (Chinese J Exp Clin Virol) 2008, 22:225-227.
37. Johne R., Müller H., Rector A., van Ranst M., Stevens H. Rolling-circle amplification of viral DNA genomes using phi29 polymerase. Trends Microbiol 2009, 17:205-211.
38. Rector A., Tachezy R., Van Ranst M. A sequence-independent strategy for detection and cloning of circular DNA virus genomes by using multiply primed rolling-circle amplification. J Virol 2004, 78:4993-4998.
39. Inoue-Nagata A.K., Albuquerque L.C., Rocha W.B., Nagata T. A simple method for cloning the complete begomovirus genome using the bacteriophage phi29 DNA polymerase. J Virol Methods 2004, 116:209-211.
40. Margeridon S., Carrouée-Durantel S., Chemin I., et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob Agents Chemother 2008, 52:3068-3073.
41. Su H.L., Liu Y.M., Ren X.Q., et al. Comparative analysis of drug resistant mutations in the reverse transcriptase domain of hepatitis B virus covalently closed circular DNA and the viral relax circle DNA. Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol) 2010, 18:818-821.
42. Thompson A.J., Nguyen T., Iser D., et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010, 51:1933-1944.
43. Chan H.L., Wong V.W., Tse A.M., et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007, 5:1462-1468.